Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Proceedings Article
  • Published:

Prognostic markers in AML: focus on CBFL

Leukemia Supplements volume 1, pages S12–S13 (2012)Cite this article

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease increasing in frequency owing to an aging population. Decisions on intensive induction treatments, intensification and allografting rely on the ability to divide an apparently homogeneous group according to risk. A wide range of clinical, cytogenetic and molecular variables may be used to inform this task; here we examine those variables useful in assessing prognosis for a patient with non-acute promyelocitic AML focusing on core binding factor leukemia. In clinical practice, when counseling an individual patient with AML, a range of well-known clinical variables (age, performance status and tumor burden) and genetic variables (cytogenetic and gene mutation) must be considered to better define the prognostic risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Smith ML, Hills RK, Grimwade D . Independent prognostic variable in acute myeloid leukemia (Review). Blood Rev 2011; 25: 39–51.

    Article  CAS  Google Scholar 

  2. Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  Google Scholar 

  3. Döhner H, Gaidzik VI . Impact of genetic features on treatment decisions in AML. Hematol Am Soc Hematol Educ Program 2011, 36–42.

  4. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705–5717.

    Article  Google Scholar 

  5. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): A survey of 110 cases from the French AML Intergroup. Blood 2003; 102: 462–469.

    Article  CAS  Google Scholar 

  6. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741–3750.

    Article  CAS  Google Scholar 

  7. Mrózek K, Marcucci G, Paschka P, Bloomfield CD . Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008; 20: 711–718.

    Article  Google Scholar 

  8. Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M et al. Down-regulation of MicroRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia 2010; 12: 866–876.

    Article  CAS  Google Scholar 

  9. Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB et al. Prognostic impact of c-KIT mutations in core binding factor leukemia. An Italian retrospective study. Blood 2006; 107: 1791–1799.

    Article  Google Scholar 

  10. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia: a survey of 161 cases from the French AML intergroup. Blood 2002; 99: 3517–3523.

    Article  CAS  Google Scholar 

  11. Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M et al. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2008; 94: 102–112.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hematology Section, Valduce Hospital, Como, Italy

    R Cairoli

  2. Division of Haematology, Niguarda Hospital, Milan, Italy

    R Cairoli, M Turrini, G Bertani & E Morra

  3. Department of Biology and Genetics for Medical Sciences, University of Milan, Milan, Italy

    A Beghini

Authors
  1. R Cairoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Beghini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Turrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Bertani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Cairoli.

Ethics declarations

Competing interests

EM has received consulting fees and lecture fees from Novartis and Bristol. The remaining authors declare no conflict of interest.

Additional information

This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cairoli, R., Beghini, A., Turrini, M. et al. Prognostic markers in AML: focus on CBFL. Leukemia Suppl 1 (Suppl 2), S12–S13 (2012). https://doi.org/10.1038/leusup.2012.9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leusup.2012.9

Keywords

This article is cited by

Search

Advanced search

Quick links